Results 141 to 150 of about 2,835 (182)

Changes in remimazolam plasma concentration associated with the Pringle maneuver during hepatectomy: a pilot study. [PDF]

J Pharm Health Care Sci
Ogawa S, Kanda H, Ito T, Suno M, Matsubara K, Luthe SK, Kawamata T.   +6 more
europepmc   +1 more source

Targeted Therapies in Inflammatory Bowel Disease: Mechanisms, Comparative Evidence, and Clinical Translation. [PDF]

J Clin Med
Pavel C, Popa A, Ilie M, Plotogea OM, Dascalu RI, Cabel T, Gunsahin D, Tincu I, Gaspar B, Pavel LE, Oaie A.   +10 more
europepmc   +1 more source

The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease

Immunotherapy, 2023
Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD).
Fanizza J, D'Amico F, Lauri G, Martinez-Dominguez SJ, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S   +11 more
openaire   +4 more sources

Evaluating filgotinib for the treatment of rheumatoid arthritis

Expert Opinion on Pharmacotherapy, 2021
Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.This review focuses on the ...
Richez, Christophe, Truchetet, Marie Elise   +1 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Filgotinib for the treatment of Crohn’s disease

Expert Opinion on Investigational Drugs, 2018
Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence.
Xavier Roblin, Stéphane Paul
exaly   +5 more sources

Filgotinib for moderately to severely active ulcerative colitis

Expert Review of Gastroenterology & Hepatology, 2022
Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.Pubmed, Scopus, and Embase databases were searched for all relevant studies ...
Alessandro Mannucci, Ferdinando D’Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese   +4 more
openaire   +3 more sources

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Lancet, The, 2021
BACKGROUND: The global prevalence of ulcerative colitis is increasing, and induction and maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety of filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor ...
Edward V Loftus, Silvio Danese, Gerhard Rogler   +2 more
exaly   +5 more sources

Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials [PDF]

Modern Rheumatology, 2022
In the treatment of rheumatoid arthritis (RA), Janus kinase inhibitors (jakinibs) represent an emerging class of targeted therapies in addition to biologics.
Arthur Kavanaugh, Yoshiya Tanaka, Iain B Mcinnes   +2 more
exaly   +2 more sources

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)

Modern Rheumatology, 2022
OBJECTIVES: To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure.
Tatsuya Atsumi, Gerd-Rüdiger Burmester, Yoshiya Tanaka   +2 more
exaly   +2 more sources